Corbus CEO Yuval Cohen, Ph.D., will participate in a number of upcoming investor conferences including a panel discussion at the B. Riley Securities Precision Oncology & Radiopharma Investor Conference this Friday, February 28th at 8am ET. For more information: https://bit.ly/4hRwk3N
Corbus Pharmaceuticals
制药业
Norwood，Massachusetts 15,856 位关注者
Committed to leveraging expertise in immunology to fulfill purpose of developing innovative new medicines
关于我们
Corbus is a precision oncology company committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ internal development pipeline includes CRB-701, a next generation antibody drug conjugate (ADC) that targets the expression of Nectin 4-on cancer cells to release a cytotoxic payload and CRB-601, and anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells. We are tenacious and will keep pushing the known boundaries to make breakthroughs where others have not.
- 网站
-
https://www.corbuspharma.com/about/careers
Corbus Pharmaceuticals的外部链接
- 所属行业
- 制药业
- 规模
- 51-200 人
- 总部
- Norwood，Massachusetts
- 类型
- 上市公司
- 创立
- 2014
- 领域
- cancer、immunotherapy、immuno-oncology、nectin-4 biology和integrin biology
地点
-
主要
获取路线
500 River Ridge Dr
US，Massachusetts，Norwood，02062
Corbus Pharmaceuticals员工
动态
-
“I am encouraged by this emerging clinical data and its similarity to what has already been established for CRB-701 in China by our partner CSPC”, stated Dominic Smethurst, Chief Medical Officer of Corbus. Learn about the data presented at ASCO GU: https://bit.ly/411ERu1 #GU25
-
The poster titled "Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701 (SYS6002) in US And UK Patients with Urothelial Cancer and other Solid Tumors" (Perez,et al) being presented today at the the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium is now available. View the poster here: https://bit.ly/4aXix9j #GU25
-
Corbus announced that data from its US and UK conducted first-in-human dose escalation clinical study (“Western study”) of CRB-701 (SYS6002) is being presented today at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The poster is being presented today, February 14th, between 11:30 am-12:45 pm PST. For details: https://bit.ly/411ERu1 #GU25
-
Attending ASCO GU? Corbus will present clinical data for CRB-701 from the Western dose escalation study tomorrow, February 14th. Learn more about the poster presentation: https://bit.ly/40Z9SyJ #GU25
-
Corbus today announced that the abstract for its first-in-human dose escalation clinical study conducted in the United States and Europe of CRB-701 has been released. The corresponding up-to-date data will be presented as a poster during the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The data from 31 patients referred to in the abstract dates to September 2024; the upcoming poster presentation will include data on 38 patients as of December 2024. For details: https://bit.ly/3WUWnPl #GU25
-
Corbus to present a poster titled "Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701 (SYS6002) in US And UK Patients with Urothelial Cancer and other Solid Tutors" at ASCO GU 2025 on Friday, February 14, 2025. Learn more: https://bit.ly/4jc9YLq #GU25
-
Tune-in today, February 5th at 2:30 p.m. ET for a fireside chat with Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, at the Guggenheim SMID Cap Biotech Conference. Watch the webcast here: https://bit.ly/3PTBJuT
-
-
Yuval Cohen, Ph.D., CEO of Corbus, will participate in an analyst-led fireside discussion during the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5th 2:30 p.m. ET. Register for the webcast here: https://bit.ly/3PTBJuT
-
-
We're #hiring a new Director, Clinical Quality Assurance (GCP) in Norwood, Massachusetts. Apply today or share this post with your network.